First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...

Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...

CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced the dosing of the first patient ...

Vir Biotechnology, Inc. VIR announced new encouraging preliminary data from its phase II SOLSTICE study. Its shares rose 19.7% on the news. The study is evaluating the safety, tolerability and ...

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...

UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...

In a new study published in GEN’s sister peer-review journal, GEN Biotechnology, titled, “Exploring Structure-Function Relationships in Engineered Receptor Performance Using Computational Structure ...

Sana Biotechnology, Inc. ((SANA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Unity Biotechnology, Inc. (NASDAQ:UBX) stock plummeted on Monday after the company released results from its latest study. The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients ...